PMVP

Insider Trades

Name	Value	Action	Price	Current Price
Orbimed Advisors LLC10 Percent Owner $1.5M1M shares SellOct 23, 2025 $1.52 --
Orbimed Advisors LLC10 Percent Owner $900k500k shares SellSep 10, 2025 $1.80 --
Mack David HenryDirector, Officer: President And CEO $62k58.4k shares SellJul 1, 2025 $1.06 --
Jalota DeepikaChief Development Officer $35k33.1k shares SellJul 1, 2025 $1.06 --
Carulli MichaelChief Financial Officer $30k28.2k shares SellJul 1, 2025 $1.06 --
Ticktin RobertGeneral Counsel & COO $25k23.2k shares SellJul 1, 2025 $1.06 --

News

zacks.comPMV Pharmaceuticals (PMVP) Loses 26% in 4 Weeks, Here's Why a Trend Reversal May be Around the Cornerzacks.comJun 10

globenewswire.comPMV Pharmaceuticals Announces Board Chair Transitionglobenewswire.comApr 22

Trade PMVP

About PMV Pharmaceuticals, Inc.

PMV Pharmaceuticals, Inc. operates as a precision oncology company focused on discovering and developing both small molecule and tumor-agnostic therapies to address p53 mutations in cancer patients. Their leading experimental drug, PC14586, is a small molecule designed to correct the p53 protein specifically when it contains the Y220C mutation, thereby restoring its natural, functional state. The company is also progressing a pipeline of other programs targeting various mutant p53 forms, including Wild-type p53 Induced-Phosphatase, R282W, R273H, and other prevalent p53 hotspot mutations. Originally known as PJ Pharmaceuticals, Inc., the firm rebranded to PMV Pharmaceuticals, Inc. in July 2013. The company was founded in 2013 and has its main operational base in Cranbury, New Jersey.

CEO: David H. Mack
IPO Date: Sep 25, 2020

Market Data

Open: $1.07
High: $1.09
Low: $1.06
Volume: 147.1K
52W High: $1.88
52W Low: $0.964

Valuation

Market Cap: $57M
Enterprise Value: $18M

Financials

Free Cash Flow: $-74M
Revenue: $0
Net Income: $-78M
Cash: $38M
Debt: $838k

Events

EarningsAug 6

EPS est. -0.43